Table 6. Safety assessment because of adverse events and abnormal laboratory values during the study.

	Bezafibrate treatment (n= 60)	Pemafibrate treatment (n= 60)
Total AEs	22 (37)	26 (43)
Treatment-related AEs	3 (5)	1 (2)
Discontinuation due to AEs	0 (0)	0 (0)
SAEs	5 (8)	6 (10)
Treatment-related SAEs	2 (3)	0 (0)
Discontinuation due to SAEs	0 (0)	0 (0)
AEs of clinical interest
CK levels of ＞5×ULN	1 (2)	0 (0)
AST and/or ALT levels of ＞3×ULN	0 (0)	0 (0)
Increase in the creatinine levels of ≥ 0.5 mg/dL and/or 25%	14 (23) ‡	3 (5)
Symptoms related to rhabdomyolysis/myopathy	0 (0)	0 (0)
Symptoms related to gallbladder disease	1 (2)	0 (0)
Symptoms related to hepatic disease	0 (0)	0 (0)
Symptoms related to pancreatic disease	0 (0)	0 (0)
Symptoms related to gastrointestinal disease	0 (0)	0 (0)

Data are presented as n (%). ^‡p＜0.005 vs. pemafibrate treatment. AEs, adverse events; SAEs, serious adverse events; CK, creatine kinase; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase.